Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions

Abstract

Optimal risk assessment for primary prevention remains highly challenging. Recent registries have highlighted major discrepancies between guidelines and daily practice. Although guidelines have improved over time and provide updated risk scores, they still fail to identify a significant proportion of at-risk individuals, who then miss out on effective prevention measures until their initial ischemic events. Cardiovascular imaging is progressively assuming an increasingly pivotal role, playing a crucial part in enhancing the meticulous categorization of individuals according to their risk profiles, thus enabling the customization of precise therapeutic strategies for patients with increased cardiovascular risks. For the most part, the current approach to patients with atherosclerotic cardiovascular disease (ASCVD) is homogeneous. However, data from registries (e.g., REACH, CORONOR) and randomized clinical trials (e.g., COMPASS, FOURIER, and ODYSSEY outcomes) highlight heterogeneity in the risks of recurrent ischemic events, which are especially higher in patients with poly-vascular disease and/or multivessel coronary disease. This indicates the need for a more individualized strategy and further research to improve definitions of individual residual risk, with a view of intensifying treatments in the subgroups with very high residual risk. In this narrative review, we discuss advances in cardiovascular imaging, its current place in the guidelines, the gaps in evidence, and perspectives for primary and secondary prevention to improve risk assessment and therapeutic strategies using cardiovascular imaging.

Assessment of Cardiovascular Risk Categories and Achievement of Therapeutic Targets in European Patients with Type 2 Diabetes

“…Employing various imaging techniques, such as coronary computed tomography angiography, magnetic resonance imaging, and others, can enhance the identification of CVD risk, and this approach is applicable in both primary and secondary prevention strategies. The utilization of these advanced imaging methods allows for a more detailed evaluation of atherosclerotic disease, myocardial damage, and overall CV health, which can play a pivotal role in the management and prevention strategies for high-risk patients [44]. As atherosclerosis is a persistent process that affects all regions of the vasculature, it is essential to improve the assessment of parameters related to the early and accelerated progression of plaque formation, instability, and rupture.…”

Coronary Tortuosity Index vs. Angle Measurement Method for the Quantification of the Tortuosity of Coronary Arteries in Non-Obstructive Coronary Disease

“…Patients with non-obstructive CAD are found to be at increased risk for major cardiovascular events, including cardiovascular death and all-cause mortality [ 36 ]. Considering that these are underdiagnosed high-risk patients, future research should include the determination of an appropriate individualized cardiovascular risk assessment tool for these patients beyond existing risk scores, which would include underutilized noninvasive cardiovascular imaging techniques [ 37 ].…”

How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review

“…Blood biomarkers, such as B-type natriuretic peptide (BNP), may not consistently exhibit elevated levels in older HFpEF patients, particularly those in sinus rhythm, with obesity, and/or normal kidney function [49,50]. However, echocardiography and BNP assessment are crucial for making a guideline-directed diagnosis of HF [51,52], and additional biomarkers, such as the soluble circulating form of the suppression of tumorigenicity two receptors (sST2), may guide prognostic stratification on admission [53,54].…”